A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving
leucémie aigüe myéloïde et syndromes myélodysplasiques liés aux inhibiteurs de la topoisomérase II
